Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: narsoplimab | 0.81 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 649 | 0.91 |
| pathways Reactome | 4 pathways; mostly immune signalling | 0.90 |
Knock down and overexpress MASP2 in a dopamine neuron, astrocyte and microglia tri-culture; measure IL-1β and TNF release and surface HLA-DR and dopamine neuron survival after α-synuclein fibril challenge.
- Cell type
- a dopamine neuron, astrocyte and microglia tri-culture
- Direction
- Both arms: public data does not say which way helps; existing compounds already reach the inhibition arm.
- Molecular readout
- IL-1β and TNF release and surface HLA-DR
- Functional readout
- dopamine neuron survival after α-synuclein fibril challenge
- Rule-out
- If neither arm moves IL-1β by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of MASP2 in a tri-culture of iPSC dopamine neurons, astrocytes and microglia; n = 3 differentiations; readouts: IL-1β and TNF release and surface HLA-DR; dopamine neuron survival after α-synuclein fibril challenge. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- MASP2 in dopamine neurons, braak-0.32 (p 0.406) → +0.14 (p 0.725)receipt 12160
Swarm cases
receipt 12160: MASP2 in dopamine neurons, braak
- power
- full sample -0.12 (p 0.646, n 18), 95% CI -0.55 to +0.37. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.14 (p 0.573, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.34 (p 0.161, n 18). could be the mix.
- skeptic
- leave-one-out range -0.25 to -0.01, sign flips 0; without severely affected donors -0.12 (p 0.646, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.64 (p 0.0039, n 18) vs -0.12 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MASP2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up MASP2 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.20 p 0.477 (needs p < 1.8e-4)
Receipts
loading the receipts